Premium
Gemcitabine‐based therapy in pancreas cancer
Author(s) -
Jacobs Andrew D.
Publication year - 2002
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.10756
Subject(s) - gemcitabine , medicine , pancreatic cancer , food and drug administration , cancer , oncology , intensive care medicine , pancreas , drug , clinical trial , pharmacology
Since its approval in 1998 by the Food and Drug Administration, gemcitabine has rapidly become accepted as a standard part of palliative therapy for patients with advanced pancreatic cancer. It has modest activity when used as a single agent, and this has led to numerous studies combining it with other active agents, including cytotoxic as well as biologic and targeted therapies. Numerous Phase II studies suggest that the combinations may have greater activity than single agent therapy. However, randomized trials concerning this are still in progress. In the current article, a variety of gemcitabine‐based novel combinations showing promising activity are reviewed. Cancer 2002;95:923–7. © 2002 American Cancer Society. DOI 10.1002/cncr.10756